Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 01 May 2017 Results (n=48) assessing genomic characterization of HER positive breast cancer patients and its predictive role for treatment efficacy with chemotherapy and trastuzumab using patient data from NCT00513292 and NCT00353483 trials, published in the Annals of Oncology
- 04 Aug 2011 Planned end date changed from Aug 2013 to Aug 2016 as reported by ClinicalTrials.gov.
- 04 Jun 2009 New trial record.